$DMAC
DiaMedica Therapeutics Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$8.71
▼-0.11%-$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateDiaMedica Therapeutics Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is DMAC up today? It is at $8.71 (+0.00%), and our scanner flagged it 47 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment DMAC spikes, and full due diligence on DMAC — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $DMAC 47 times in the last 30 days. Create a free account to track $DMAC, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on DMAC from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for DMAC today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystDiaMedica Therapeutics Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →We could not reach SEC EDGAR, so the dilution check did not run. This is not a clean result - verify on EDGAR before trading.
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Pauls Dietrich John Officer | Acquired (grant/award) | +60K 0.1% of company | added 88% | 129K | n/a | Aug 10, 26 |
Semba Charles Pauling Director | Acquired (grant/award) | +3K | added 7.5% | 48K | $28K at $8.42 | Jan 2, 26 |
Giuffre Randall Michael Director | Acquired (grant/award) | +6K 0.01% of company | added 1.6% | 399K | $52K at $8.42 | Jan 2, 26 |
Parsons James T. Director | Acquired (grant/award) | +10K 0.02% of company | added 11% | 98K | $85K at $8.42 | Jan 2, 26 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +73K 0.1% of company | added 0.8% | 8.83M | $626K at $8.57 | Nov 25, 25 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +40K 0.07% of company | added 0.5% | 8.75M | $318K at $7.89 | Nov 24, 25 |
Parsons James T. Director | Other | 12K 0.02% of company | added 16% | 88K | $26K at $2.20 | Nov 21, 25 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +209K 0.4% of company | added 2.5% | 8.71M | $1.5M at $7.41 | Nov 21, 25 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +128K 0.2% of company | added 1.5% | 8.50M | $952K at $7.41 | Nov 20, 25 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +240K 0.4% of company | added 3.0% | 8.38M | $1.7M at $7.21 | Nov 19, 25 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +183K 0.3% of company | added 2.3% | 8.13M | $1.2M at $6.75 | Nov 18, 25 |
Stahlberg Jan Beneficial Owner (10%) | Bought (open market) | +187K 0.3% of company | added 2.4% | 7.95M | $1.2M at $6.52 | Nov 17, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on DMAC from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for DMAC today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
DMAC last traded at $8.71, up 0.00% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
DiaMedica Therapeutics Inc. Common Stock (DMAC) is next expected to report earnings on Wednesday, November 11, 2026, about 16 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The DMAC Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged DMAC 47 times in the last 30 days.
DMAC (DiaMedica Therapeutics Inc. Common Stock) trades on XNAS, with a market cap of about $470M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge DMAC for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$DMAC discussion
Sign in to ask a question or join the discussion.